Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 2Phase 4 1

Status

Not yet recruiting 3Recruiting 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Conditions

Myasthenia Gravis 6Autoimmune Diseases 3Neuromuscular Diseases 1Muscle Weakness 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × telitacicept × Clear all
NCT06456580 2026-05-07

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Vor Biopharma

Phase 3 Recruiting
180 enrolled

Myasthenia Gravis

NCT07249632 2026-04-09

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

RemeGen Co., Ltd.

Phase 3 Recruiting
120 enrolled

Myasthenia Gravis

NCT07298928 2026-03-06

A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis

The Children's Hospital of Zhejiang University School of Medicine

Phase NA Not yet recruiting
30 enrolled

Myasthenia Gravis

NCT05737160 2025-05-23

Study of Telitacicept in Generalized Myasthenia Gravis

RemeGen Co., Ltd.

Phase 3 Completed
114 enrolled

Autoimmune Diseases, Myasthenia Gravis, Muscle Weakness

NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase NA Not yet recruiting
60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

NCT06723548 2024-12-09

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase 4 Not yet recruiting
30 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡